Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Protagonist Therapeutics, Inc. on June 17, 2026. The record date for the meeting was April 22, 2026, with 64,305,185 shares of common stock entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan approvals rather than financial performance data.
Material Changes and Voting Results
Stockholders approved four key proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Dinesh V. Patel, Ph.D., and Lewis T. "Rusty" Williams, M.D., Ph.D., were elected as Class I directors. Dr. Patel received 48,714,702 votes "For," while Dr. Williams received 45,371,193 votes "For."
- Proposal 2 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 53,412,559 votes "For" and 3,164,702 votes "Against."
- Proposal 3 (Auditor Ratification): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 59,371,487 votes "For."
- Proposal 4 (Equity Incentive Plan): The 2026 Equity Incentive Plan was approved with 47,745,562 votes "For." This plan replaces the 2016 plan and authorizes the issuance of shares comprising the remaining 2016 plan shares, 650,000 new shares, and shares returning to the plan due to expiration or forfeiture.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks. The 2026 Equity Incentive Plan allows for awards subject to performance goals, but specific targets are not detailed in this summary.
Investor Verification Checklist
- Review the full text of the 2026 Equity Incentive Plan (Exhibit 10.1) to understand specific vesting terms and performance conditions.
- Consult the Definitive Proxy Statement on Schedule 14A filed on April 28, 2026, for detailed descriptions of the equity plan and director nominees.
- Verify the total number of shares authorized under the new plan, noting the addition of 650,000 new shares to the carryover balance from the 2016 plan.